SCHEMBL982157

SCHEMBL982157

CC(C)(C)OC(=O)n1ccc(CBr)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.36
GPR119 Q8TDV5 2/20 0.34
AKT1 P31749 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
BUB1 O43683 1/20 0.33
NR1H2 P55055 1/20 0.33
HTR6 P50406 1/20 0.32
ABCB1 P08183 1/20 0.32
FAAH O00519 1/20 0.32
KLK7 P49862 2/20 0.32
KLK5 Q9Y337 1/20 0.32
STS P08842 1/20 0.32
LIPC P11150 1/20 0.32
LIPG Q9Y5X9 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM4 P08173 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6853937 0.85 GPR119 (0.38) BCHEGPR119MEN1KMT2AL3MBTL1
SCHEMBL18190298 0.85 L3MBTL1 (0.36) BCHEGPR119MEN1KMT2AL3MBTL1
SCHEMBL28125734 0.83 KLK7 (0.36) BCHEGPR119MEN1KMT2AL3MBTL1
SCHEMBL14213914 0.83 GPR119 (0.35) BCHEGPR119MEN1KMT2AL3MBTL1
SCHEMBL18133541 0.81 BUB1 (0.35) BCHEGPR119MEN1KMT2AL3MBTL1
SCHEMBL1018306 0.78 BCHE (0.38) BCHEGPR119MEN1KMT2AL3MBTL1
SCHEMBL14966067 0.78 APLNR (0.41) BCHEGPR119MEN1KMT2ABUB1
SCHEMBL11911366 0.76 GPR119 (0.39) BCHEGPR119MEN1KMT2AL3MBTL1
SCHEMBL7528678 0.76 ESR2 (0.40) BCHEGPR119MEN1KMT2AL3MBTL1
SCHEMBL17242214 0.76 NR1H2 (0.38) BCHEGPR119AKT1NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962626-B2 Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) 2015-02-24 US disclosed
EP-2241569-B1 THIENOPYRIDAZINE COMPOUNDS, THEIR PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND USES ZHEJIANG MED XINCHANG PHARM (CN) 2012-05-23 EP disclosed
US-20110009415-A1 Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses WU, ZHANGGUI (CN) 2011-01-13 US disclosed
EP-2241569-A1 THIENOPYRIDAZINE COMPOUNDS, THEIR PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND USES Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) 2010-10-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009415-A1 Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses CYP3A5, ABCC5, DPYD BCHE 3109/4885GPR119 1844/4885AKT1 3891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.